Sponsor hub
EMD Serono Research & Development Institute, Inc. clinical trial failures
Review 26 stopped clinical trials from EMD Serono Research & Development Institute, Inc., including disease areas, phases, and classified stop reasons.
This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 6 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.
Dominant stop reasons
- OPERATIONAL
- 12
- OTHER/UNKNOWN
- 8
- EFFICACY/FUTILITY
- 4
- SAFETY
- 2
Notable sponsors
- EMD Serono Research & Development Institute, Inc.
- 26
Related phases
- Phase I
- 12
- Phase II
- 10
- Phase III
- 4
Crawlable stopped-trial records
Open ExploreShowing up to 26 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.
Phase I Metastatic or Locally Advanced Unresectable Solid Tumors trial by EMD Serono Research & Development Institute, Inc.. Stop reason: OPERATIONAL.
Overarching portfolio-level review of the company's oncology pipeline resulted in early termination of the study. The study was not terminated due to safety.
Phase III Head and Neck Cancer trial by EMD Serono Research & Development Institute, Inc.. Stop reason: OPERATIONAL.
The study was terminated by sponsor as the development program was discontinued due to outcome of phase III Trilynx study.
Phase I Advanced Solid Tumor trial by EMD Serono Research & Development Institute, Inc.. Stop reason: OPERATIONAL.
Sponsor Decision
Phase III Squamous Cell Carcinoma of the Head and Neck trial by EMD Serono Research & Development Institute, Inc.. Stop reason: EFFICACY/FUTILITY.
Study has crossed the pre-defined futility boundary at the Interim Analysis.
Phase I Head and Neck Cancer trial by EMD Serono Research & Development Institute, Inc.. Stop reason: OTHER/UNKNOWN.
No major safety concerns were identified in HyperlynX study, but Lack of evidence of efficacy of meaningful clinical benefit.
Phase II Dermatomyositis trial by EMD Serono Research & Development Institute, Inc.. Stop reason: EFFICACY/FUTILITY.
Based on interim analyses for futility
Phase I Advanced Solid Tumors trial by EMD Serono Research & Development Institute, Inc.. Stop reason: OPERATIONAL.
Study was terminated due to decision made not to proceed with the clinical trial DDRiver 521, that has not yet commenced enrolment, for strategic reasons.
Phase II Relapsing-remitting Multiple Sclerosis trial by EMD Serono Research & Development Institute, Inc.. Stop reason: EFFICACY/FUTILITY.
Results from the EVOLUTION clinical trials showed evobrutinib did not meet its primary endpoint of annualized relapse rate for up to 156 weeks compared to oral teriflunomide in both studies.
Phase II Urothelial Carcinoma trial by EMD Serono Research & Development Institute, Inc.. Stop reason: OPERATIONAL.
Trial withdrawn based on re-prioritization of the clinical development path for tuvusertib. No subjects were enrolled.
Phase I Advanced Solid Tumors trial by EMD Serono Research & Development Institute, Inc.. Stop reason: EFFICACY/FUTILITY.
The study was terminated due to pre-specified futility criteria met.
Phase I Refractory or Relapsed Solid Tumors trial by EMD Serono Research & Development Institute, Inc.. Stop reason: OTHER/UNKNOWN.
Based on the limited activity observed with avelumab monotherapy in the pediatric population, the Phase II study part was cancelled.
Phase II Non-small Cell Lung Cancer trial by EMD Serono Research & Development Institute, Inc.. Stop reason: SAFETY.
Based on recommendations by an external Independent data Monitoring Committee (IDMC), Sponsor decided to discontinue this clinical study due to a low likelihood of achieving superiority in the efficacy endpoints versus standard of care.
Phase I Solid Tumors trial by EMD Serono Research & Development Institute, Inc.. Stop reason: OPERATIONAL.
The study was terminated early per sponsor decision to halt further development of M3541 due to pharmaceutical and PK/pharmacodynamics properties that precluded further clinical development.
Phase II Biliary Tract Cancer trial by EMD Serono Research & Development Institute, Inc.. Stop reason: SAFETY.
Based on a review of data conducted by the Independent Data Monitoring Committee (IDMC), Sponsor decided to discontinue this study as the study was unlikely to achieve the primary objective of overall survival.
Phase II Triple Negative Breast Neoplasms trial by EMD Serono Research & Development Institute, Inc.. Stop reason: OPERATIONAL.
The study was prematurely discontinued by the sponsor due to probability of success which was too low to justify the continuation of recruitment.
Phase I Multiple Myeloma trial by EMD Serono Research & Development Institute, Inc.. Stop reason: OPERATIONAL.
The study was early discontinued due to lack of participant enrollment.
Phase II Colorectal Neoplasms trial by EMD Serono Research & Development Institute, Inc.. Stop reason: OTHER/UNKNOWN.
The study was terminated early due to operational challenges identifying suitable participants for screening in the study.
Phase I Advanced Solid Tumors trial by EMD Serono Research & Development Institute, Inc.. Stop reason: OPERATIONAL.
As part of a portfolio-level management of the company's oncology pipeline, it was decided to stop the next phase of internal development of the MetAP2 (M8891) program to enable realization of other opportunities within the oncology portfolio.
Phase III Relapsing-remitting Multiple Sclerosis trial by EMD Serono Research & Development Institute, Inc.. Stop reason: OTHER/UNKNOWN.
Following analysis of open label extension (OLE) data from RMS phase 2 study (MS200527- 0086), it was determined that a change in active comparator warranted in phase 3 RMS comprised of trial MS200527-0074. Consequently, this trial terminated early.
Phase III Relapsing-remitting Multiple Sclerosis trial by EMD Serono Research & Development Institute, Inc.. Stop reason: OTHER/UNKNOWN.
Following analysis of open label extension (OLE) data from RMS phase 2 study (MS200527- 0086), it was determined that a change in active comparator warranted in phase 3 RMS comprised of trial MS200527-0073. Consequently, this trial terminated early.
Phase I Advanced Solid Tumor trial by EMD Serono Research & Development Institute, Inc.. Stop reason: OPERATIONAL.
Trial withdrawn based on portfolio prioritization; oral ATRi M1774 in combination with niraparib is under investigation in DDRiver Solid Tumor 301
Phase II Systemic Lupus Erythematosus trial by EMD Serono Research & Development Institute, Inc.. Stop reason: OTHER/UNKNOWN.
Study is completed; primary analysis completed.
Phase II IgA Nephropathy trial by EMD Serono Research & Development Institute, Inc.. Stop reason: OPERATIONAL.
Study was terminated early as per sponsor decision due to unexpectedly slow enrollment.
Phase I Small Cell Lung Cancer trial by EMD Serono Research & Development Institute, Inc.. Stop reason: OPERATIONAL.
Enrollment in the study was prematurely terminated due to recruitment challenges and not due to concerns of safety for the participants.
Phase I Metastatic or Locally Advanced Unresectable Solid Tumors trial by EMD Serono Research & Development Institute, Inc.. Stop reason: OTHER/UNKNOWN.
The study was terminated early due to lackluster pharmacodynamic data that showed no significant reduction of plasma kynurenine at steady state of M4112.
Phase II Systemic Sclerosis-associated Interstitial Lung Disease trial by EMD Serono Research & Development Institute, Inc.. Stop reason: OTHER/UNKNOWN.
Difficulties experienced in identifying participants who meet the eligibility criteria of the trial.